Management of Asymptomatic Diastolic Dysfunction

Core Management Principles

The American College of Cardiology recommends focusing on controlling underlying conditions, such as hypertension, coronary artery disease, and diabetes, rather than initiating heart failure medications in asymptomatic patients with diastolic dysfunction, as there is no proven benefit from pharmacologic therapy in the absence of symptoms 1
The therapeutic approach centers on addressing causative and precipitating factors rather than treating the diastolic dysfunction itself, with blood pressure control being the most critical intervention, particularly in elderly women 1

Coronary revascularization should be considered when symptomatic or demonstrable myocardial ischemia adversely affects diastolic function, with a Class IIa recommendation 1, 2

Echocardiographic assessment should be performed to establish baseline diastolic function parameters and left ventricular dimensions, with repeat evaluation within 2-3 months if the chronicity of the condition is uncertain 3
Ongoing clinical assessment is necessary to detect the onset of symptoms, as this changes management significantly 3

Normal daily physical activity, including mild forms of exercise, is appropriate for asymptomatic patients with normal left ventricular systolic function, while avoiding isometric exercise and considering exercise testing before participation in competitive athletics 3

The American College of Cardiology recommends diuretics, used judiciously to reduce elevated filling pressures without significantly reducing cardiac output, and nitrates to lower elevated filling pressures, in symptomatic patients 1, 2
Rate control agents, such as beta-blockers or calcium channel blockers, should be used to optimize diastolic filling time, particularly if atrial fibrillation develops 1, 2
The American College of Cardiology advises against aggressively treating asymptomatic diastolic dysfunction with heart failure medications, as the evidence does not support this approach, and patients with mild to moderate diastolic dysfunction without symptoms have an excellent outcome with treatment of underlying conditions alone 1, 3

La disfunción diastólica afecta el llenado ventricular, deteriorando la relajación ventricular y reduciendo la distensibilidad del ventrículo, lo que conduce a elevación de la presión de llenado ventricular, presión auricular izquierda, presión venosa pulmonar y presión capilar pulmonar, manifestándose clínicamente como disnea en pacientes con insuficiencia cardíaca diastólica, según el American College of Cardiology 4, 5, 6
La insuficiencia cardíaca diastólica se presenta principalmente en mujeres ancianas, la mayoría con hipertensión, y puede limitar su tolerancia al ejercicio y calidad de vida, según el American College of Cardiology 5, 7

El tratamiento se basa en varios principios terapéuticos, incluyendo el control de factores causales y precipitantes, como isquemia miocárdica, hipertensión, hipertrofia miocárdica y constricción miocárdica/pericárdica, según la European Heart Journal 8
El tratamiento farmacológico incluye beta-bloqueantes, antagonistas del calcio tipo verapamilo, inhibidores de la ECA y diuréticos, según la European Heart Journal 8, 9
La revascularización coronaria debe considerarse en pacientes con enfermedad arterial coronaria en quienes la isquemia miocárdica sintomática o demostrable afecta adversamente la función diastólica, según el American College of Cardiology 5, 7

El diagnóstico de insuficiencia cardíaca diastólica requiere tres condiciones: presencia de signos o síntomas de insuficiencia cardíaca, función sistólica ventricular izquierda normal o solo levemente anormal, y evidencia de disfunción diastólica ventricular izquierda, según la European Heart Journal 10

Stage A (at‑risk) – Individuals have cardiovascular risk factors such as hypertension, diabetes, coronary disease, or obesity but no structural heart disease or heart‑failure symptoms. The American College of Cardiology/American Heart Association (ACC/AHA) defines this stage [11][12].
Stage B (pre‑heart‑failure) – Individuals exhibit structural heart disease or echocardiographic evidence of diastolic dysfunction (impaired relaxation) without any current or prior heart‑failure symptoms. ACC/AHA classification [11][12].

Aggressive blood‑pressure control is the single most important intervention to prevent further myocardial stiffening, especially in older adults and women. ACC/AHA recommends targeting optimal BP 13.
Coronary artery disease treatment – When myocardial ischemia is present or suspected, revascularization should be considered because ischemia can worsen diastolic function. ACC/AHA guidance 13.
Diabetes optimization – Tight glycemic control is advised to limit adverse effects on myocardial relaxation. ACC/AHA guidance 13.
Weight management – Reducing excess body weight is a modifiable strategy to improve diastolic function and overall cardiovascular risk. ACC/AHA guidance 12.

Do not initiate heart‑failure specific drugs (ACE inhibitors, ARBs, beta‑blockers, diuretics) in patients without symptoms; there is no proven benefit in this population and the ACC explicitly advises against routine use. ACC/AHA recommendation 11.

If symptoms develop (e.g., dyspnea, fatigue, reduced exercise tolerance), management shifts to Stage C and specific therapies become appropriate. ACC/AHA outlines this transition 11.
- Rate‑control agents (beta‑blockers or non‑dihydropyridine calcium‑channel blockers) are recommended to maintain adequate diastolic filling time, particularly when atrial fibrillation occurs. European Society of Cardiology (ESC) guidance 14.
- ACE inhibitors or ARBs may improve myocardial relaxation and reduce hypertrophy in symptomatic patients. ESC guidance 14.
- Judicious diuretic use can lower elevated filling pressures without markedly decreasing cardiac output when volume overload appears. ESC guidance 14.
Prevent tachycardia – Rapid heart rates shorten diastolic filling time and should be avoided in all patients with diastolic dysfunction. ACC/AHA recommendation 13.

Aggressive modification of risk factors, especially blood‑pressure control, is associated with reduced morbidity and mortality in patients with early diastolic dysfunction. ACC/AHA evidence statement 11.